Overview

Study of Pembrolizumab in Patients With Early-Stage NK/T-cell Lymphoma, Nasal Type

Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test how well pembrolizumab shrinks Early-Stage NK/T-cell Lymphoma (ENKTL) in participants who have not yet received chemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Treatments:
Pembrolizumab